Controlling methicillin resistant Staphylococcus aureus

BMJ

Volumn 327, Issue 7425, 2003, Pages 1177-1178

  Duckworth, Georgia ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL ENZYME; BETA LACTAMASE; DALFOPRISTIN PLUS QUINUPRISTIN; FLUCLOXACILLIN; LEUKOCIDIN; LINEZOLID; METICILLIN; PENICILLIN G; VANCOMYCIN;

BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERIAL GENETICS; BACTERIAL STRAIN; BONE INFECTION; EDITORIAL; ENDEMIC DISEASE; EPIDEMIC; GENETIC VARIABILITY; HEALTH CARE COST; HEALTH CARE QUALITY; HUMAN; INFECTION CONTROL; INFECTION RATE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PENICILLIN RESISTANCE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROCESS DEVELOPMENT; STAPHYLOCOCCUS INFECTION; UNITED KINGDOM;

HUMANS; METHICILLIN RESISTANCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 0344826042     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.327.7425.1177     Document Type: Editorial

References (12)

1. Reacher MH, Shah A, Livermore DM, Wale MC, Graham C, Johnson AP, et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ 2000; 320: 213–6.
2. Public Health Laboratory Service. Staphylococcus aureus bacteraemia: England and Wales January to December 2000. Commun Dis Rep CDR Wkly [serial online] 2001 [cited 5 September 2003];11(7):Bacteraemia. http://www.hpa.org.uk/cdr/PDFfiles/2001/cdr0701.pdf (accessed 30 Sep 2003).
3. Oliveira DC, Tomasz A, de Lencastre H. The evolution of pandemic clones of methicillin-resistant Staphylococcus aureus: identification of two ancestral backgrounds and the associated mec elements. Microb Drug Resist 2001; 7: 349–61.
4. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135–6.
5. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin-United States 2002. MMWR Morb Mortal Wkly Rep 2002; 51: 565–7.
6. Crowcroft NS, Lamagni TL, Rooney C, Catchpole M, Duckworth G. Mortality from methicillin resistant Staphylococcus aureus [electronic response to Howard et al. Mortality from methicillin resistant Staphylococcus aureus]. BMJ 2003. http://bmj.com/cgi/eletters/326/7387/501/a#30165 (accessed 15 Aug 2003).
7. Dufour P, Gillet Y, Bes M, Lina G, Vandenesch F, Floret D, et al. Community-acquired methicillin-resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002; 35: 819–24.
8. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus-Minnesota and North Dakota, 1997–1999. MMWR Morb Mortal Wkly Rep 1999; 48: 707–10.
9. Cooper BS, Stone SP, Kibbler CC, Cookson BD, Roberts J, Medley GF, et al. Systematic review of isolation policies in the hospital management of methicillin resistant Staphylococcus aureus: a review of the literature with epidemiological and economic modelling. Health Technology Assessment 97/07/01 (in press).
10. Commission for Health Improvement. Methicillin resistant Staphylococcus aureus (MRSA) bacteraemia improvement score. London: CHI, 2003. http://www.chi.nhs.uk/Ratings/Trust/Indicator/indicatorDescriptionShort.asp?indicatorId=1610 (accessed 19 Aug 2003).
11. Verhoef J, Beaujean D, Blok H, Baars A, Meyler A, van der Werken C, et al. A Dutch approach to methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 1999; 18: 461–6.
12. Muto CA, Jernigan JA, Ostrowsky BE, Richet HM, Jarvis WR, Boyce JM, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003; 24: 362–86.